Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 43

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 4
Chunk 43
---
 technology that generates high-value yields of active ingredients from natural based resources for use in novel cosmeceutical, nutraceutical and therapeutics products. The Company’s two value-driving products, oat beta glucan and avenanthramides, are found in many household name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits.
 
The Company is also dedicated to the development of its therapeutic assets and has established a development pipeline to potentially address unmet medical needs across a number of indications, including potential treatment of inflammation and immune-based diseases.
 
During the third quarter of 2024, the Company made a strategic decision to discontinue its AIM Biologicals, Amyotrophic Lateral Sclerosis (ALS), and Delayed Clearance Parathyroid Hormone programs. This decision was influenced by several factors, including increasingly challenging timelines and costs associated with reaching the next value inflection point in pre-clinical development.
 
On August 27, 2024, the Company announced that the Phase 3 DETECT-trial evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency (CGHD) had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science’s business offering natural-based products. Therefore, while macimorelin for the diagnosis of Adult Growth Hormone Deficiency is still on the market, the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD and is exploring and validating several options for its commercialization with adults. Such strategic options include the potential to divest this asset.

Active Ingredients
 
The Company’s operations also include those of the wholly owned subsidiary, Ceapro Inc, focused on the development and commercialization of “active ingredients” derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Company’s primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries using proprietary technology, natural, renewable resources and developing innovative products, technologies and delivery systems.
 
Active ingredient products include:
 

●                                        A commercial line of                                    
     natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), 
      oat powder, oat oil, and oat peptides, which are marketed to the personal